• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. Mar 1997; 71(3): 2292–2302.
PMCID: PMC191338

A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.

Abstract

The development of safe and effective vaccines remains a major goal in the prevention, and perhaps treatment, of infectious diseases. Ideally, a single vaccine would confer protection against several pathogens and would induce both cellular and humoral arms of the immune response. We originally demonstrated that two virus-specific cytotoxic T-lymphocyte (CTL) epitopes, from the same virus but presented by different major histocompatibility complex alleles, when linked in tandem as minigenes in a recombinant vaccinia virus, could confer complete protection against subsequent viral challenge. In the study, we extended this approach, which we termed string of beads, expanding the immunogenic scope in two ways: first, by introduction of T helper (Th) and B-cell (antibody) epitopes alongside CTL epitopes and second, by including immunogenic sequences from a variety of infectious agents, five viruses and one bacterium. The vaccine (VV-sv) comprises CTL epitopes from Sendai virus, respiratory syncytial virus, and lymphocytic choriomeningitis virus (LCMV); Th epitopes from vesicular stomatitis virus and Mycobacterium tuberculosis; and an antibody epitope from mengovirus. The construct contains a single start codon, and the epitopes are linked directly, without intervening spacer amino acids. There was some concern that the combination of several normally immunodominant epitopes might result in a new hierarchy of dominance, in which certain epitopes predominated and others exhibited reduced immunogenicity. However we show that when analyzed in tissue culture and in vivo, all six epitopes are expressed. CTL and Th cells are induced in vivo, along with neutralizing antibody. The induced immunity is biologically relevant: after VV-sv immunization, the antimengovirus antibody confers protection against mengovirus challenge. Similarly, CTL induced by the LCMV epitope protected mice against challenge with this agent. Thus, a polyvalent, minigene-based vaccine can simultaneously induce several classes of immune response and thereby can confer protection against diverse pathogens.

Full Text

The Full Text of this article is available as a PDF (313K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ahmed R. Immunological memory against viruses. Semin Immunol. 1992 Apr;4(2):105–109. [PubMed]
  • Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990 May 1;171(5):1815–1820. [PMC free article] [PubMed]
  • Aichinger G, Lechler RI. Endogenous pathway of class II presentation. Biochem Soc Trans. 1995 Aug;23(3):657–660. [PubMed]
  • An LL, Pamer E, Whitton JL. A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection. Infect Immun. 1996 May;64(5):1685–1693. [PMC free article] [PubMed]
  • Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 1994 Jun 2;369(6479):407–410. [PubMed]
  • Brooks AG, McCluskey J. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells. J Immunol. 1993 May 1;150(9):3690–3697. [PubMed]
  • Burkhart C, Freer G, Castro R, Adorini L, Wiesmüller KH, Zinkernagel RM, Hengartner H. Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus. J Virol. 1994 Mar;68(3):1573–1580. [PMC free article] [PubMed]
  • Chimini G, Pala P, Sire J, Jordan BR, Maryanski JL. Recognition of oligonucleotide-encoded T cell epitopes introduced into a gene unrelated to the original antigen. J Exp Med. 1989 Jan 1;169(1):297–302. [PMC free article] [PubMed]
  • Cole GA, Hogg TL, Woodland DL. The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells. Int Immunol. 1994 Nov;6(11):1767–1775. [PubMed]
  • Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell. 1991 Sep 20;66(6):1145–1153. [PubMed]
  • Deres K, Schumacher TN, Wiesmüller KH, Stevanović S, Greiner G, Jung G, Ploegh HL. Preferred size of peptides that bind to H-2 Kb is sequence dependent. Eur J Immunol. 1992 Jun;22(6):1603–1608. [PubMed]
  • Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanik BC, Doyle CK, DeMartino GN, Bevan MJ, Forman JM, Slaughter CA. Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. J Immunol. 1994 Apr 15;152(8):3884–3894. [PMC free article] [PubMed]
  • Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature. 1993 Sep 16;365(6443):262–264. [PubMed]
  • Dutko FJ, Oldstone MB. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol. 1983 Aug;64(Pt 8):1689–1698. [PubMed]
  • Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med. 1995 Dec 1;182(6):1865–1870. [PMC free article] [PubMed]
  • Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med. 1992 Feb 1;175(2):481–487. [PMC free article] [PubMed]
  • Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, Kloetzel PM. A role for the proteasome regulator PA28alpha in antigen presentation. Nature. 1996 May 9;381(6578):166–168. [PubMed]
  • Hahn YS, Hahn CS, Braciale VL, Braciale TJ, Rice CM. CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med. 1992 Nov 1;176(5):1335–1341. [PMC free article] [PubMed]
  • Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992 Mar 6;255(5049):1264–1266. [PubMed]
  • Klavinskis LS, Whitton JL, Joly E, Oldstone MB. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology. 1990 Oct;178(2):393–400. [PubMed]
  • Klavinskis LS, Whitton JL, Oldstone MB. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol. 1989 Oct;63(10):4311–4316. [PMC free article] [PubMed]
  • Kulkarni AB, Collins PL, Bacik I, Yewdell JW, Bennink JR, Crowe JE, Jr, Murphy BR. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol. 1995 Feb;69(2):1261–1264. [PMC free article] [PubMed]
  • Lanzavecchia A. Antigen presentation by B lymphocytes: a critical step in T-B collaboration. Curr Top Microbiol Immunol. 1986;130:65–78. [PubMed]
  • Muir S, Weintraub JP, Hogle J, Bittle JL. Neutralizing antibody to Mengo virus, induced by synthetic peptides. J Gen Virol. 1991 May;72(Pt 5):1087–1092. [PubMed]
  • Oldstone MB, Tishon A, Eddleston M, de la Torre JC, McKee T, Whitton JL. Vaccination to prevent persistent viral infection. J Virol. 1993 Jul;67(7):4372–4378. [PMC free article] [PubMed]
  • Palmert MR, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Usiak MF, Younkin LH, Younkin SG. Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease. Science. 1988 Aug 26;241(4869):1080–1084. [PubMed]
  • Schulz M, Aichele P, Vollenweider M, Bobe FW, Cardinaux F, Hengartner H, Zinkernagel RM. Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur J Immunol. 1989 Sep;19(9):1657–1667. [PubMed]
  • Selin LK, Nahill SR, Welsh RM. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J Exp Med. 1994 Jun 1;179(6):1933–1943. [PMC free article] [PubMed]
  • Sheng N, Zhang J, Whitton JL, McKee T. A rapid and simple method for determining the DNA sequences of fragments inserted into vaccinia virus. Biotechniques. 1993 May;14(5):781–784. [PubMed]
  • Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BE, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol. 1996 Jul 15;157(2):822–826. [PubMed]
  • Thomson SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ, Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5845–5849. [PMC free article] [PubMed]
  • Villanueva MS, Fischer P, Feen K, Pamer EG. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity. 1994 Sep;1(6):479–489. [PubMed]
  • Vordermeier HM, Harris DP, Moreno C, Ivanyi J. Promiscuous T cell recognition of an H-2 IA-presented mycobacterial epitope. Eur J Immunol. 1994 Sep;24(9):2061–2067. [PubMed]
  • Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992 Apr 2;356(6368):443–446. [PubMed]
  • Whitton JL. Induction of protective immunity using minigenes. Ann N Y Acad Sci. 1994 Aug 15;730:107–117. [PubMed]
  • Whitton JL, Gebhard JR, Lewicki H, Tishon A, Oldstone MB. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol. 1988 Mar;62(3):687–695. [PMC free article] [PubMed]
  • Whitton JL, Oldstone MB. Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med. 1989 Sep 1;170(3):1033–1038. [PMC free article] [PubMed]
  • Whitton JL, Sheng N, Oldstone MB, McKee TA. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol. 1993 Jan;67(1):348–352. [PMC free article] [PubMed]
  • Whitton JL, Tishon A, Lewicki H, Gebhard J, Cook T, Salvato M, Joly E, Oldstone MB. Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol. 1989 Oct;63(10):4303–4310. [PMC free article] [PubMed]
  • Yokoyama M, Zhang J, Whitton JL. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol. 1995 Apr;69(4):2684–2688. [PMC free article] [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...